By analyzing the associations between sunitinib sensitivity and the activity of STAT3 signaling using the Cancer Therapeutics Response Portal, we found that STAT3 signaling was significantly activated in cells with a higher IC50 of sunitinib (Fig. 3a). Here, STAT3 is linked to cancer.